Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$1.70 -1.7%	$1.71	$1.40 ▼ $7.88	$76.79M	1.59	339,218 shs	39,329 shs
GTHX G1 Therapeutics	$7.15	$7.13	$1.08 ▼ $7.19	$373.81M	1.66	1.70 million shs	N/A
KPTI Karyopharm Therapeutics	$4.31 -1.8%	$5.08	$3.51 ▼ $16.95	$37.93M	0.23	77,082 shs	75,082 shs
PRTA Prothena	$6.07 -0.2%	$6.66	$4.32 ▼ $25.42	$327.27M	-0.07	786,711 shs	1.14 million shs
VERU Veru	$0.58 +0.1%	$0.56	$0.45 ▼ $1.42	$85.24M	-0.8	1.94 million shs	1.44 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	0.00%	0.00%	+2.98%	+9.49%	-67.11%
GTHX G1 Therapeutics	0.00%	0.00%	0.00%	0.00%	+213.60%
KPTI Karyopharm Therapeutics	0.00%	+0.23%	+2.09%	+17.38%	-66.27%
PRTA Prothena	0.00%	+6.29%	+32.46%	-50.89%	-70.54%
VERU Veru	0.00%	-6.68%	+14.04%	+18.65%	-30.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPIX ESSA Pharma	1.9728 of 5 stars	2.0	2.0	0.0	0.0	3.3	2.5	1.3
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	4.2409 of 5 stars	3.5	1.0	0.0	4.6	3.3	2.5	0.6
PRTA Prothena	3.1581 of 5 stars	4.2	2.0	0.0	0.0	1.6	1.7	1.3
VERU Veru	2.554 of 5 stars	3.5	3.0	0.0	0.0	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	2.00	Hold	$2.00	17.65% Upside
GTHX G1 Therapeutics	2.00	Hold	N/A	N/A
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	902.32% Upside
PRTA Prothena	2.33	Hold	$31.50	418.95% Upside
VERU Veru	3.00	Buy	$4.00	587.52% Upside

Current Analyst Ratings Breakdown

Latest EPIX, KPTI, GTHX, PRTA, and VERU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/28/2025	PRTA Prothena	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform
5/27/2025	PRTA Prothena	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$110.00 ➝ $81.00
5/27/2025	PRTA Prothena	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$78.00 ➝ $29.00
5/27/2025	PRTA Prothena	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
5/27/2025	PRTA Prothena	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$6.00
5/27/2025	PRTA Prothena	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/27/2025	PRTA Prothena	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $14.00
5/27/2025	PRTA Prothena	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
GTHX G1 Therapeutics	$58.20M	6.42	N/A	N/A	$0.68 per share	10.51
KPTI Karyopharm Therapeutics	$145.24M	0.26	N/A	N/A	($22.10) per share	-0.20
PRTA Prothena	$135.16M	2.42	N/A	N/A	$9.05 per share	0.67
VERU Veru	$16.89M	5.05	N/A	N/A	$0.22 per share	2.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-23.48%	-22.86%	8/4/2025 (Estimated)
GTHX G1 Therapeutics	-$47.97M	-$0.62	N/A	N/A	N/A	-76.93%	-136.98%	-39.33%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
PRTA Prothena	-$122.31M	-$2.08	N/A	N/A	N/A	-79.94%	-21.61%	-19.32%	8/6/2025 (Estimated)
VERU Veru	-$37.80M	-$0.24	N/A	N/A	N/A	-223.85%	-128.51%	-76.51%	8/6/2025 (Estimated)

Latest EPIX, KPTI, GTHX, PRTA, and VERU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
5/8/2025	Q1 2025	PRTA Prothena	-$0.92	-$1.12	-$0.20	-$1.12	$8.18 million	$2.83 million
5/8/2025	Q2 2025	VERU Veru	-$0.06	-$0.05	+$0.01	-$0.05	$0.73 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
GTHX G1 Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	67.15	67.15
GTHX G1 Therapeutics	1.34	2.48	2.12
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
PRTA Prothena	N/A	9.00	9.00
VERU Veru	N/A	3.80	3.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
GTHX G1 Therapeutics	24.21%
KPTI Karyopharm Therapeutics	66.44%
PRTA Prothena	97.08%
VERU Veru	47.16%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	15.50%
GTHX G1 Therapeutics	6.11%
KPTI Karyopharm Therapeutics	2.75%
PRTA Prothena	9.20%
VERU Veru	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
GTHX G1 Therapeutics	170	52.28 million	49.09 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.40 million	Optionable
PRTA Prothena	130	53.83 million	48.88 million	Optionable
VERU Veru	230	146.58 million	124.30 million	Optionable

EPIX, KPTI, GTHX, PRTA, and VERU Headlines

Recent News About These Companies

Veru And Two Other Penny Stocks To Consider

June 26, 2025 | finance.yahoo.com

Veru Inc (FMW.DU)

June 26, 2025 | nz.finance.yahoo.com

Veru reports positive results for enobosarm in weight management study

June 26, 2025 | uk.investing.com

Why Veru Inc. Is Rising In Pre-market? - Nasdaq

June 26, 2025 | nasdaq.com

Veru (NASDAQ:VERU) Stock Price Crosses Below 200-Day Moving Average - Here's What Happened

June 25, 2025 | marketbeat.com

One Veru Insider Raised Stake By 150% In Previous Year

June 22, 2025 | finance.yahoo.com

Scholar Rock drug preserves muscle in obesity trial

June 18, 2025 | yahoo.com

Traders Buy High Volume of Put Options on Veru (NASDAQ:VERU)

June 17, 2025 | marketbeat.com

Veru (NASDAQ:VERU) Stock Crosses Below 200-Day Moving Average - Here's Why

June 17, 2025 | marketbeat.com

Veru Inc. to Engage with Investors at BTIG Obesity Health Forum on June 18, 2025

June 11, 2025 | quiverquant.comQ

Veru to Participate in the Virtual BTIG Obesity Health Forum

June 11, 2025 | globenewswire.com

Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vital Farms to leave

May 30, 2025 | seekingalpha.com

Veru’s obesity drug roughly as safe as Wegovy; Keros’ board fight

May 28, 2025 | endpts.comE

Muscle-sparing obesity drug safe for Phase 3 trial, Veru says

May 28, 2025 | yahoo.com

Veru Inc. Announce Positive Topline Safety Data from Phase 2b QUALITY Study of Enobosarm Combined with Semaglutide

May 28, 2025 | quiverquant.comQ

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 28, 2025 | globenewswire.com

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 26, 2025 | seekingalpha.com

Youngsters at Dunstable school hear about the dangers of knife crime

May 22, 2025 | msn.com

Veru Inc.: Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 8, 2025 | finanznachrichten.de

Veru signals Q3 2025 regulatory clarity for enobosarm Phase 3 trial

May 8, 2025 | msn.com

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPIX, KPTI, GTHX, PRTA, and VERU Company Descriptions

ESSA Pharma NASDAQ:EPIX

$1.70 -0.03 (-1.73%)

As of 04:00 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

G1 Therapeutics NASDAQ:GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Karyopharm Therapeutics NASDAQ:KPTI

$4.31 -0.08 (-1.82%)

As of 04:00 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Prothena NASDAQ:PRTA

$6.07 -0.01 (-0.16%)

As of 04:00 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Veru NASDAQ:VERU

$0.58 +0.00 (+0.05%)

As of 04:00 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time